MENU

SLDB Stock Solid Biosciences (SLDB, $2.89) Moving Average Convergence Divergence (MACD) Histogram turned positive on May 22, 2025

A.I.dvisor
at Tickeron.com
Loading...
SLDB - Solid Biosciences
MACD signal
Bullish Trend
Odds of UP Trend
Tickeron
MACD signal
Price: $2.89
Daily change: +$0.19 (+7.04%)
Daily volume: 1.8M
Capitalization: $224M
Industry: Biotechnology
This is a Bullish indicator signaling SLDB's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 40 similar cases where SLDB's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

SLDB in upward trend: 10-day moving average crossed above 50-day moving average on June 05, 2025

The 10-day moving average for SLDB crossed bullishly above the 50-day moving average on June 05, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 21, 2025. You may want to consider a long position or call options on SLDB as a result. In of 72 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SLDB just turned positive on May 22, 2025. Looking at past instances where SLDB's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

SLDB moved above its 50-day moving average on June 02, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where SLDB advanced for three days, in of 224 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLDB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SLDB broke above its upper Bollinger Band on June 04, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.119) is normal, around the industry mean (16.332). P/E Ratio (0.000) is within average values for comparable stocks, (59.787). SLDB's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.227). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (263.647).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SLDB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLDB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of novel gene therapy platform for advancing disease

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
500 Rutherford Avenue
Phone
+1 617 337-4680
Employees
88
Web
https://www.solidbio.com